BRIEF-Billiontoone Announces Selection Of Northstar Select® As The New Liquid Biopsy Test

Reuters

Jan 06

Jan 6 (Reuters) - BillionToOne Inc BLLN.O:

BILLIONTOONE ANNOUNCES SELECTION OF NORTHSTAR SELECT® AS THE NEW LIQUID BIOPSY TEST FOR LC-SCRUM-TRY CLINICAL STUDY AT NATIONAL CANCER CENTER HOSPITAL EAST
BILLIONTOONE- ULTRA-SENSITIVE LIQUID BIOPSY EXPANDING PRECISION MEDICINE ACCESS IN JAPAN WITH TREATMENT-RESISTANT NON-SMALL CELL LUNG CANCER

Source text: ID:nPn1d2jGca

Further company coverage: BLLN.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2601816803"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601816803\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601816803?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 23:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601816803","market":"us","top_or_hot":-1,"title":"BRIEF-Billiontoone Announces Selection Of Northstar Select® As The New Liquid Biopsy Test","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Billiontoone Announces Selection Of Northstar Select® As The New Liquid Biopsy Test </title></head><body><p><span>Jan 6 (Reuters)</span><span> - </span>BillionToOne Inc <span>BLLN.O</span>:</p><ul><li><p>BILLIONTOONE ANNOUNCES SELECTION OF NORTHSTAR SELECT® AS THE NEW LIQUID BIOPSY TEST FOR LC-SCRUM-TRY CLINICAL STUDY AT NATIONAL CANCER CENTER HOSPITAL EAST</p></li><li><p>BILLIONTOONE- ULTRA-SENSITIVE LIQUID BIOPSY EXPANDING PRECISION MEDICINE ACCESS IN JAPAN WITH TREATMENT-RESISTANT NON-SMALL CELL LUNG CANCER</p></li></ul><p>Source text: <span>ID:nPn1d2jGca</span></p><p>Further company coverage: <span>BLLN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Billiontoone Announces Selection Of Northstar Select® As The New Liquid Biopsy Test</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Billiontoone Announces Selection Of Northstar Select® As The New Liquid Biopsy Test\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-06 23:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Billiontoone Announces Selection Of Northstar Select® As The New Liquid Biopsy Test </title></head><body><p><span>Jan 6 (Reuters)</span><span> - </span>BillionToOne Inc <span>BLLN.O</span>:</p><ul><li><p>BILLIONTOONE ANNOUNCES SELECTION OF NORTHSTAR SELECT® AS THE NEW LIQUID BIOPSY TEST FOR LC-SCRUM-TRY CLINICAL STUDY AT NATIONAL CANCER CENTER HOSPITAL EAST</p></li><li><p>BILLIONTOONE- ULTRA-SENSITIVE LIQUID BIOPSY EXPANDING PRECISION MEDICINE ACCESS IN JAPAN WITH TREATMENT-RESISTANT NON-SMALL CELL LUNG CANCER</p></li></ul><p>Source text: <span>ID:nPn1d2jGca</span></p><p>Further company coverage: <span>BLLN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA2KWDPY:1","article_id":"2601816803","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601816803","pubTimestamp":1767712280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Billiontoone Announces Selection Of Northstar Select As The New Liquid Biopsy Test Jan 6 (Reuters) - BillionToOne Inc BLLN.O:BILLIONTOONE ANNOUNCES SELECTION OF NORTHSTAR SELECT AS THE NEW LIQUI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","BLLN":"BillionToOne, Inc."},"translate_title":"简介-Billiontoone宣布选择Northstar Select®作为新的液体活检测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLLN":0.9},"content_text":"BRIEF-Billiontoone Announces Selection Of Northstar Select® As The New Liquid Biopsy Test Jan 6 (Reuters) - BillionToOne Inc BLLN.O:BILLIONTOONE ANNOUNCES SELECTION OF NORTHSTAR SELECT® AS THE NEW LIQUID BIOPSY TEST FOR LC-SCRUM-TRY CLINICAL STUDY AT NATIONAL CANCER CENTER HOSPITAL EASTBILLIONTOONE- ULTRA-SENSITIVE LIQUID BIOPSY EXPANDING PRECISION MEDICINE ACCESS IN JAPAN WITH TREATMENT-RESISTANT NON-SMALL CELL LUNG CANCERSource text: ID:nPn1d2jGcaFurther company coverage: BLLN.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}